NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free LXEO Stock Alerts $12.24 -0.06 (-0.49%) (As of 10:45 AM ET) Add Compare Share Share Today's Range$12.18▼$12.4850-Day Range$12.05▼$16.5852-Week Range$9.00▼$22.33Volume20,106 shsAverage Volume106,187 shsMarket Capitalization$403.19 millionP/E RatioN/ADividend YieldN/APrice Target$20.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lexeo Therapeutics alerts: Email Address Lexeo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.9% Upside$20.80 Price TargetShort InterestBearish5.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.17 out of 5 starsMedical Sector774th out of 924 stocksBiological Products, Except Diagnostic Industry129th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexeo Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.21% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 6.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXEO. Previous Next 1.9 News and Social Media Coverage News SentimentLexeo Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Lexeo Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lexeo Therapeutics are expected to remain at ($3.04) per share in the coming year.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Lexeo Therapeutics Stock (NASDAQ:LXEO)Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Read More LXEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXEO Stock News HeadlinesApril 27, 2024 | americanbankingnews.comBrokers Issue Forecasts for Lexeo Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LXEO)April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy AdvancementsMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 26, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Lexeo Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:LXEO)April 24, 2024 | uk.investing.comLexeo Therapeutics secures rights to advance gene therapyApril 24, 2024 | americanbankingnews.comLexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Lock-Up Period Set To End on May 1stApril 22, 2024 | finance.yahoo.comLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyApril 16, 2024 | marketwatch.comLexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia CardiomyopathyMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 16, 2024 | markets.businessinsider.comLexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-marketApril 16, 2024 | finance.yahoo.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyApril 16, 2024 | globenewswire.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia CardiomyopathyApril 9, 2024 | seekingalpha.comLexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay OffMarch 14, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)March 13, 2024 | globenewswire.comLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingMarch 13, 2024 | markets.businessinsider.comOptimistic Outlook for Lexeo Therapeutics with Strong Clinical and Financial Performance Justifying Buy RatingMarch 12, 2024 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To KnowMarch 11, 2024 | msn.comLexeo Therapeutics announces $95M private equity placementMarch 11, 2024 | globenewswire.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 11, 2024 | globenewswire.comLexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingFebruary 6, 2024 | msn.comLexeo Therapeutics Bolsters Leadership with Key HiresFebruary 5, 2024 | msn.comLexeo Therapeutics announces new executive appointmentsFebruary 5, 2024 | finance.yahoo.comLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsJanuary 29, 2024 | seekingalpha.comLexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer'sJanuary 19, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO) and Andlauer Healthcare Group (OtherANDHF)January 7, 2024 | seekingalpha.comLXEO Lexeo Therapeutics, Inc.January 6, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC CapitalSee More Headlines Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/02/2024Next Earnings (Estimated)6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CUSIPN/A CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$20.80 High Stock Price Target$23.00 Low Stock Price Target$19.00 Potential Upside/Downside+69.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio7.21 Quick Ratio7.21 Sales & Book Value Annual Sales$650,000.00 Price / Sales620.29 Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book2.87Miscellaneous Outstanding Shares32,940,000Free FloatN/AMarket Cap$403.19 million OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. R. Nolan Townsend (Age 43)CEO & Director Comp: $864.34kDr. Eric Adler M.D. (Age 50)Chief Medical Officer & Head of Research Comp: $623.4kMs. Jenny R. Robertson (Age 49)Chief Business & Legal Officer Comp: $617.9kDr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardDr. Paul B. McCormac Ph.D. (Age 54)Chief Technical Officer Comp: $471.73kDr. Jordan Shin M.D.Ph.D., Senior Vice President of Clinical Development & Translational Science, CardiologyDr. Jordan S. Dubow M.D. (Age 45)Head of CNS Clinical Development Dr. Sandi See Tai M.D. (Age 53)Chief Development Officer Mr. Ryan McHenryVP & Corporate ControllerMore ExecutivesKey CompetitorsVoyager TherapeuticsNASDAQ:VYGRTourmaline BioNASDAQ:TRMLiTeos TherapeuticsNASDAQ:ITOSAdaptive BiotechnologiesNASDAQ:ADPTReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 4,781 shares on 5/1/2024Ownership: 0.015%Cornell UniversityBought 126,258 shares on 4/29/2024Ownership: 0.383%Eventide Asset Management LLCBought 3,002,831 shares on 2/20/2024Ownership: 11.268%Omega Fund Management LLCBought 2,157,623 shares on 2/15/2024Ownership: 8.096%Blackstone Inc.Bought 696,110 shares on 2/15/2024Ownership: 2.612%View All Insider TransactionsView All Institutional Transactions LXEO Stock Analysis - Frequently Asked Questions Should I buy or sell Lexeo Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexeo Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXEO shares. View LXEO analyst ratings or view top-rated stocks. What is Lexeo Therapeutics' stock price target for 2024? 6 brokerages have issued 1 year price targets for Lexeo Therapeutics' stock. Their LXEO share price targets range from $19.00 to $23.00. On average, they predict the company's share price to reach $20.80 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price. View analysts price targets for LXEO or view top-rated stocks among Wall Street analysts. How have LXEO shares performed in 2024? Lexeo Therapeutics' stock was trading at $13.42 at the beginning of the year. Since then, LXEO shares have decreased by 8.8% and is now trading at $12.24. View the best growth stocks for 2024 here. Are investors shorting Lexeo Therapeutics? Lexeo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 783,500 shares, an increase of 63.4% from the March 15th total of 479,500 shares. Based on an average daily volume of 106,600 shares, the days-to-cover ratio is currently 7.3 days. Approximately 4.9% of the company's shares are sold short. View Lexeo Therapeutics' Short Interest. When is Lexeo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024. View our LXEO earnings forecast. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released its quarterly earnings results on Monday, March, 11th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at $11.00 per share. When did the company's lock-up period expire? Lexeo Therapeutics' lock-up period expired on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period. Who are Lexeo Therapeutics' major shareholders? Lexeo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cornell University (0.38%) and BNP Paribas Financial Markets (0.01%). View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXEO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
